• Explore /
  • Videos & Slides
  • / Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

Abstract Video & Slides

Presenter

null

Fiona Simpkins, MD

Penn Medicine Abramson Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2024 ASCO Annual Meeting

Session Type

Clinical Science Symposium

Session Title

Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03462342

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 5510)

DOI

10.1200/JCO.2024.42.16_suppl.5510

Abstract #

5510

Abstract Disclosures

Similar Videos & Slides

Speaker: Stephanie L. Wethington, MD, MSc

Videos & Slides

2015 ASCO Annual Meeting

Using Social Media to Learn and Communicate: It Is Not About the Tweet

Using Social Media to Learn and Communicate: It Is Not About the Tweet

Speaker: Michael A. Thompson, MD, PhD

Speaker: Joyce Liu, MD, MPH

Speaker: Jared Cohen, MD